Limits...
Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus

Targeting peptide expressed with Lamp2b was expressed on the external surface of exosomes. (a) Schematic representation of production, harvest and re-administration of targeted self-exosomes for gene delivery. (b) Size distribution of RVG exosomes as measured by NTA peaking at 88 nm diameter. (c) Electron micrograph of phosphotungstic acid stained RVG exosomes. Reproduced with permission134. Copyright 2014, Nature.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4440443&req=5

Figure 9: Targeting peptide expressed with Lamp2b was expressed on the external surface of exosomes. (a) Schematic representation of production, harvest and re-administration of targeted self-exosomes for gene delivery. (b) Size distribution of RVG exosomes as measured by NTA peaking at 88 nm diameter. (c) Electron micrograph of phosphotungstic acid stained RVG exosomes. Reproduced with permission134. Copyright 2014, Nature.

Mentions: To improve their targeting ability, the exosomes were modified artificially in many ways132, 134, 135. A conceptual work was conducted by Alvarez-Erviti et al (Figure 9)134. Exosomes generated from immature DCs were hypotoxic and hypo-immunogenic since the low expression of immunostimulatory markers, such as MHC II, CD80 and CD86 on the surface. A peptide derived from the Rabies Virus Glycoprotein (RVG) was fused to Lamp2b (an exosomal membrane protein). These RVG-exosomes could bind to nicotinic acetylcholine receptor expressed on the BBB so as to increase the brain targeting ability. Through this carrier, siRNA was specifically delivered to the neurons, microglia, and oligodendrocytes in the brain with ~ 60% decreased expression of target gene. A subsequent study by Ohno et al developed EGF or GE11 peptide fused exosomes to deliver microRNA (miRNA) to epidermal growth factor receptor (EGFR)-expressing breast cancer cells135. As expected, the miRNA was successfully delivered to the xenograft cancer tissue via the exosomes after iv administration. Besides, chemotherapeutic drug, DOX, was also loaded into bioengineered iRGD-Lamp2b exosomes via electroporation (EE, ~ 20%) to target αν integrin-positive cancer cells114. This modified exosome showed specific tumor targeting and a powerful tumor growth inhibition.


Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

Targeting peptide expressed with Lamp2b was expressed on the external surface of exosomes. (a) Schematic representation of production, harvest and re-administration of targeted self-exosomes for gene delivery. (b) Size distribution of RVG exosomes as measured by NTA peaking at 88 nm diameter. (c) Electron micrograph of phosphotungstic acid stained RVG exosomes. Reproduced with permission134. Copyright 2014, Nature.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4440443&req=5

Figure 9: Targeting peptide expressed with Lamp2b was expressed on the external surface of exosomes. (a) Schematic representation of production, harvest and re-administration of targeted self-exosomes for gene delivery. (b) Size distribution of RVG exosomes as measured by NTA peaking at 88 nm diameter. (c) Electron micrograph of phosphotungstic acid stained RVG exosomes. Reproduced with permission134. Copyright 2014, Nature.
Mentions: To improve their targeting ability, the exosomes were modified artificially in many ways132, 134, 135. A conceptual work was conducted by Alvarez-Erviti et al (Figure 9)134. Exosomes generated from immature DCs were hypotoxic and hypo-immunogenic since the low expression of immunostimulatory markers, such as MHC II, CD80 and CD86 on the surface. A peptide derived from the Rabies Virus Glycoprotein (RVG) was fused to Lamp2b (an exosomal membrane protein). These RVG-exosomes could bind to nicotinic acetylcholine receptor expressed on the BBB so as to increase the brain targeting ability. Through this carrier, siRNA was specifically delivered to the neurons, microglia, and oligodendrocytes in the brain with ~ 60% decreased expression of target gene. A subsequent study by Ohno et al developed EGF or GE11 peptide fused exosomes to deliver microRNA (miRNA) to epidermal growth factor receptor (EGFR)-expressing breast cancer cells135. As expected, the miRNA was successfully delivered to the xenograft cancer tissue via the exosomes after iv administration. Besides, chemotherapeutic drug, DOX, was also loaded into bioengineered iRGD-Lamp2b exosomes via electroporation (EE, ~ 20%) to target αν integrin-positive cancer cells114. This modified exosome showed specific tumor targeting and a powerful tumor growth inhibition.

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus